---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-22-000014"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2022-03-25T23:59:59+00:00"
generated_at: "2026-06-26T17:37:00.523920+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways establishes The Centre for Mental Health Research and Innovation with King's College London and SLaM

## Summary
- Up to £12M investment over 10-year term; Centre to accelerate psychedelic therapy research and new care models.
- Initial focus on COMP360 psilocybin therapy for TRD, PTSD, and anorexia nervosa; expects 650-700 patients over 5 years.
- Facilities to be built at Bethlem Royal Hospital in London; state-of-the-art clinical trial space.
- Partnership with UK's largest NHS mental health trust (SLaM) and King's College London's IoPPN.

## SEC filing metadata
- accession: 0001816590-22-000014
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2022-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659022000014/0001816590-22-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659022000014/cmps-20220324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-22-000014
- JSON: https://secwatch.observer/filing/0001816590-22-000014.json
- Plain text: https://secwatch.observer/filing/0001816590-22-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.